Marlene Maria Speth

Marlene Maria Speth

Auto-generated profile, based on publicly available information

Marlene Maria Speth

ENT, Imperial College Healthcare NHS Trust, London, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in ASAIO Journal
Verified
Journal Article
Open access
MSMarlene Speth
Marlene Speth
FMFrank Münch
Frank Münch
APAriawan Purbojo
Ariawan Purbojo
MGMartin Glöckler
Martin Glöckler
OTOkan Toka
Okan Toka
ARAndré Rüffer
André Rüffer
This study reports a single-centre experience of the Medos Deltastream diagonal-pump (DP3) for extracorporeal cardiac, pulmonary, or combined support in a single-center pediatric cohort. Twenty-seven consecutive patients with 28 runs of the DP3 between January 2013 and June 2014 were included for analysis. Median patient age, weight, and duration of support were 278 days (range: 0 days–14.2 years), 7.2 kg (range: 2.5–39 kg), and 8 days (range: 2–69 days). Midline sternotomy (n = 20, 71.4%) or cervical approaches (n = 8, 28.6%) were used for cannulation. The DP3 was employed for either veno-arterial extracorporeal life support (ECLS, n = 16), veno-venous extracorporeal membrane oxygenation (ECMO, n = 5), or ventricular assist devices (right ventricular assist device [RVAD], n = 1; left ventricular assist device [LVAD], n = 1; and univentricular assist device [UNIVAD], n = 5). Three patients initially supported with ECLS were switched to UNIVAD and one patient with UNIVAD was changed to ECLS. Required flow for neonates (n = 8) ranged between 0.2 and 0.75 L/min. Irreversible pump damage occurred in one patient during deairing after air block. Successful weaning, 30 day and hospital survival were 89.3% (n = 25), 85.7% (n = 24), and 71.4% (n = 20). All patients on UNIVAD, who did not require further extracorporeal respiratory assist, survived. In conclusion, the DP3 can be used for individual patient demands and adapted to their most suitable method of support. Meticulous flow adjustments render this pump highly effective for extracorporeal support particularly in pediatric patients.

27 November 2024 in Current Opinion in Otolaryngology & Head and Neck Surgery
Verified
Journal Article
Closed access
MSMarlene M. Speth
Marlene M. Speth
DLDavid T. Liu
David T. Liu
GBGerold Besser
Gerold Besser
ASAhmad R. Sedaghat
Ahmad R. Sedaghat
Purpose of review: Especially with the advent of biologics which have originally been prescribed primarily for pulmonary disease, the interconnections between asthma and chronic rhinosinusitis are becoming even more apparent. Biologics can now also be prescribed for chronic rhinosinusitis in some countries. But what is the epidemiology, pathophysiology and treatment of both diseases? Recent findings: This review covers the epidemiology, pathophysiology, morbidity and treatment of both diseases. Specifically, this review highlights the interdependencies of both diseases and potential future treatment options. Summary: This review aims to alert physicians to go beyond treating only one of the diseases, but rather to get a broader picture of the diseases and treatment options.

12 January 2022 in HNO
Verified
Journal Article
Closed access
PDF file
MSM. M. Speth
M. M. Speth
USU. S. Speth
U. S. Speth
ASA. R. Sedaghat
A. R. Sedaghat
THT. Hummel
T. Hummel

13 April 2022 in DGNeurologie
Verified
Journal Article
Closed access
PDF file
MSM. M. Speth
M. M. Speth
USU. S. Speth
U. S. Speth
ASA. R. Sedaghat
A. R. Sedaghat
THT. Hummel
T. Hummel

18 June 2024 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
ASAnouk Schmid
Anouk Schmid
NANader Ahmad
Nader Ahmad
SHSebastian Haubitz
Sebastian Haubitz
MSMarlene Maria Speth
Marlene Maria Speth
We introduce the case of a male patient in his 60s who was admitted to our emergency department with a persisting sore throat for the last 3 weeks and dysphagia. Fibre-endoscopic evaluation revealed an asymmetry at the base of the tongue. In combination with elevated white cell count and C reactive protein, a computerized tomography showed a superinfected thyroglossal duct cyst. Intravenous antibiotics were initiated, and the patient was taken to the operating room for cervicotomy. The microbiological swab taken intraoperatively detected Nocardia paucivorans. Additional imaging revealed disseminated nocardiosis with cerebral and pulmonary manifestations. The patient was treated with oral trimethoprim/sulfamethoxazole and, over time, showed complete remission of central nervous system lesions and improvement of pulmonary involvement. Following this, the treatment was stopped 8 months after the initial diagnosis. In this report, we discuss treatment standards and outcomes of nocardiosis based on our management strategies of our patient.

16 November 2026 in Head & Neck
Verified
Journal Article
Open access
MRMischa de Ridder
Mischa de Ridder
GBGerben Eise Breimer
Gerben Eise Breimer
PBPaolo Bossi
Paolo Bossi
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald
FBFrancesco Bussu
Francesco Bussu
JRJohannes Rijken
Johannes Rijken
Purpose: Cancer of the nasal vestibule (CNV) differs anatomically and clinically from both sinonasal and cutaneous squamous cell carcinoma, yet lacks formal recognition as a separate clinical entity and topographical subsite; whether it is also biologically distinct has not yet been investigated. EUSICA/INSICA advocates for formal recognition of CNV and a unified classification, treatment, and translational framework. Method: Published literature on CNV, including population‐based cohorts, T‐classification studies, brachytherapy outcomes, and quality‐of‐life data, was reviewed by an international multidisciplinary EUSICA/INSICA expert panel to formulate consensus recommendations. Finding: CNV shows favorable outcomes, drains preferentially to facial and submandibular nodes, and is amenable to organ‐preserving radiotherapy, in particular brachytherapy. It is staged using four non‐uniform systems; multicenter validation in 609 patients from 21 centers supported the prognostic utility of the New Rome classification integrated with clinical nodal status. Validated CNV‐specific quality‐of‐life instruments are lacking. Compared with NCCN‐defined high‐risk cutaneous SCC of the nose, CNV differs in topography, pattern of local spread, prognostic landmarks, nodal behavior, and treatment paradigm. Comparative molecular data versus cutaneous and sinonasal SCC are not yet available. Conclusion: EUSICA/INSICA calls for formal recognition of CNV as a distinct ICD‐O‐3 subsite, incorporation of the New Rome T classification into UICC/AJCC TNM, standardized organ‐preserving treatment, and dedicated translational research, including comparative molecular studies to determine whether its clinical distinctness has a biological basis.